Cytodyn has had it’s own shot at that bar, a reminder there were GBM patients in the solid tumor basket trial and there were some patients in the TNBC Leronlimab trial with glioblastoma secondary tumors that were ALSO responding to Leronlimab. As we know, this drug does cross the blood brain barrier, so it is open season for high CCR5 expressing brain tumors…glioblastoma among them but also astrocyte’s so by inference probably this includes astrocytoma’s. The preclinical study Dr. Jay announced where Cytodyn just supplies the drug will act as an accelerant. I’m not surprised that among his 4 near term priorities is to get the data they are sitting on published…the medical oncology community needs to be aware of it. Glioblastoma diagnosis is bleak, if memory serves 5% 5 year survival. We need this drug out of the barn and on the run against the subset of cancers it can bend that survival curve.